NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128173	Articles
104823	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 10/20/2025 at 14:50, 3 months 19 days ago

NanoViricides Announces Promising Measles Treatment

NanoViricides NV-387 Antiviral Drug Measles Treatment Emergency Use
PRESS RELEASE

published on 10/20/2025 at 14:45, 3 months 19 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial

NanoViricides NV-387 Emergency Use Measles Virus Phase I
BRIEF

published on 10/15/2025 at 14:50, 3 months 24 days ago

NanoViricides Pursues Dual-Track Clinical Strategy for NV-387

Respiratory Viruses Broad-spectrum Antiviral Phase II Trials NV-387 Development MPox Trial
BRIEF

published on 10/15/2025 at 14:50, 3 months 24 days ago

NanoViricides poursuit une stratégie clinique à double voie pour le NV-387

Antiviral À Large Spectre Essais De Phase II Développement NV-387 Essai MPox Virus Respiratoires
PRESS RELEASE

published on 10/15/2025 at 14:45, 3 months 24 days ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects

Respiratory Viral Infections NV-387 NanoViricides Inc. Analyst Report Clinical Development Strategy
BRIEF

published on 09/30/2025 at 14:50, 4 months 8 days ago

NanoViricides' NV-387 Advances in Clinical Trials

NanoViricides NV-387 Clinical Trials Antiviral Therapy Funding Challenges
BRIEF

published on 09/30/2025 at 14:50, 4 months 8 days ago

Progrès du NV-387 de NanoViricides dans les essais cliniques

NanoViricides NV-387 Essais Cliniques Thérapie Antivirale Défis De Financement
PRESS RELEASE

published on 09/30/2025 at 14:45, 4 months 8 days ago

NanoViricides, Inc. Has Filed its Annual Report
NanoViricides reports progress on antiviral NV-387 in Phase II clinical trials with potential to revolutionize treatment for respiratory viral infections. Annual report highlights achievements and funding status

NanoViricides NV-387 Clinical Trials Respiratory Infections Antiviral
BRIEF

published on 09/11/2025 at 14:35, 4 months 27 days ago

NanoViricides sera présenté au congrès mondial LSX à Boston

NanoViricides NV-387 Essais Cliniques Médicament Antiviral Congrès LSX
BRIEF

published on 09/11/2025 at 14:35, 4 months 27 days ago

NanoViricides to Present at LSX World Congress in Boston

NanoViricides NV-387 Clinical Trials Antiviral Drug LSX Congress

Accesswire

Published on 02/08/2026 at 21:00, 1 hour 6 minutes ago

Banyan Gold Extends Airstrip and High-Grade Mineralization to 350m Vertical Depth, Yukon, Canada
Published on 02/07/2026 at 01:00, 1 day 21 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 22 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 2 days ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 2 days 6 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 1 day 1 hour ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 1 day 5 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 1 day 5 hours ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 2 days 2 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 2 days 4 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 2 days 3 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 2 days 3 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 2 days 6 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 2 days 6 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 14 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE